Despite attempts to improve the definitions of ambiguous leukemia (ALAL) during the last two decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study iBFM-AMBI2012 on 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (5yEFS) of patients with acute lymphoblastic leukemia (ALL)-type primary therapy (80±4%) was superior to that of children who received acute myeloid leukemia (AML)-type or combined-type treatments (36±7.2% and 50±12%, respectively). When ALL- or AML-specific gene fusions were excluded, 5yEFS of CD19pos leukemia was 83±5.3% on ALL-type primary treatment compared to 0±0% and 28±14% on AML-type and combined-type primary treatment, respectively. Superiority of ALL-type treatment was documented in single-population mixed phenotype ALAL (using WHO and/or EGIL definitions), and in the bilineal ALAL. Treatment with ALL-type protocols is recommended for the majority of pediatric patients with ALAL, including cases with CD19pos ALAL. AML-type of treatment is preferred in a minority of ALAL cases with CD19neg and no other lymphoid features ALALs. No overall benefit of transplantation was documented and it could be introduced in some patients with a poor response to treatment. As no clear indicator was found for a change to the treatment type, this is to be considered only in cases with 5% blast or greater after remission induction. The results provide a basis for a prospective trial. Key points The largest cohort of ambiguous leukemias to date reveals a better prognosis of children who started on lymphoid-directed treatment. Myeloid type of primary treatment correlated with dismal outcomes in CD19pos leukemias.
β-thalassemia is one of the most prevalent monogenetic disorders worldwide. In the most severe form – transfusion-dependent β-thalassemia – patients require long-term red cell transfusions for survival. The only potentially curative option is stem cell transplantation, reserved only for young children with HLA-identical donor. Thompson et al. present a study of 22 patients with transfusion-dependent β-thalassemia...
B cell precursor acute lymphoblastic leukemia (BCP ALL), the most common malignancy in children, consists of many genetic subtypes with different prognosis. Using RNA sequencing (RNAseq) helped identify new genetic subtypes recently -- DUX4, ZNFR384, BCR-ABL1-like, etc. Despite this progress, about 10% of BCP ALL cases have unclear genetic background. Discovering new genetic subtypes and their prognosis are important for stratification and potential use of target therapy. Using RNAseq in 1998 childhood and adult BCP ALLs, Mullighan and his team defined new BCP ALL subtypes -- PAX5alt and PAX5 p.Pro80Arg. They showed that PAX5 alterations could be initiating, sub-type defining events, and not secondary events as has been considered in previous studies. According to the results, PAX5alt and PAX5 p.Pro80Arg have inferior outcomes in children. The authors also determined the most common deregulated pathways in each subtype. Overall, Mullighan's team shows the importance of RNAseq in defining new genetic subtypes, which can lead to better stratification of patients.
Bone marrow failure (BMF) in children is often suspected to be inherited but many patients remain undiagnosed. The authors studied a large cohort (179) of these undiagnosed patients (Fanconi anemia excluded). Using whole exome sequencing (WES) of skin fibroblasts (which secured the germline nature of identified mutations) combined with clinical analysis, they provided a molecular diagnosis in 48% patients of their cohort. They found some new genes that are not usually mentioned at BMF diagnosis (SAMD9, SAMD9L, ERCC6L2, MECOM) and some genes that could possibly contribute to BMF (BRCA2, TP53), but further investigation and functional tests are needed. Identifying new genes, their frequency and clinical presentations will be useful in obtaining an accurate genetic diagnosis at medical evaluation. For example, patients with SAMD9/SAMD9L mutations might improve spontaneously. Longer follow-up of these patients is necessary for decisions on bone marrow transplantation. This paper is of clinical importance because it is the basis for further investigations on inherited BMF pathogenesis, classification and risk prediction.